James R. Rigas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James R. Rigas has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Hassan Ghazal
Laboratory of Precision Medicine and One Health (MedPreOne), School of Medicine, Mohammed VI University of Sciences and Health, Casablanca, Morocco
2 shared publications K. H. Dragnev
2 shared publicationsA. Evans
Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH
1 shared publicationA. Negro-Vilar
Dartmouth Medcl Sch, Lebanon, NH; Ligand pharmaceuticals, Inc, San Diego, CA
1 shared publication- Afshin Dowlati
University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
1 shared publication - Alan L Crim
M2Gen, Tampa, FL, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 9469-9481
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
Purpose: To characterize programmed cell death ligand-1 (PD-L1) expression in relation to survival and gene mutation status in patients with advanced NSCLC. The study also explored the influence of tumor mutational burden (TMB) on PD-L1 expression and patient characteristics. Patients and methods: Adult patients with histologically or cytologically documented Stage IIIB/Stage IV/recurrent/progressive NSCLC, Eastern Cooperative Oncology Group performance status 0 to 3, and >2 lines of prior systemic treatment regimens were included in this retrospective analysis. Patients were treated from 1997 to 2015 at H. Lee Moffitt Cancer Center and Research Institute, Tampa, or at 7 community centers across the United States. PD-L1 expression level was determined using the VENTANA PD-L1 (SP263) Assay. EGFR and KRAS mutation status and ALK rearrangements were determined by targeted DNA sequencing; these were obtained from clinical records where targeted DNA sequencing was not performed. TMB was calculated as the total number of somatic mutations per sample. Results: From a total of 136 patients included in the study, 23.5% had tumors with high PD-L1 expression (≥25%). There were no significant differences in patient characteristics, overall survival (OS), and progression-free survival (PFS) between patients with high PD-L1 expression (median OS: 39.5 months; median PFS: 15.8 months) vs low PD-L1 expression (Conclusion: In this retrospective analysis, survival outcomes of patients with advanced NSCLC were comparable by PD-L1 expression level. EGFR and KRAS mutation status were not found to be significantly associated with PD-L1 expression level, while TMB was weakly associated with PD-L1 expression level. Overall, PD-L1 expression level was not observed to be an independent prognostic biomarker in this cohort of patients with advanced NSCLC treated with chemotherapy.
- 1 November 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 9469-9481
Open AccessA Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
Purpose: To characterize programmed cell death ligand-1 (PD-L1) expression in relation to survival and gene mutation status in patients with advanced NSCLC. The study also explored the influence of tumor mutational burden (TMB) on PD-L1 expression and patient characteristics. Patients and methods: Adult patients with histologically or cytologically documented Stage IIIB/Stage IV/recurrent/progressive NSCLC, Eastern Cooperative Oncology Group performance status 0 to 3, and >2 lines of prior systemic treatment regimens were included in this retrospective analysis. Patients were treated from 1997 to 2015 at H. Lee Moffitt Cancer Center and Research Institute, Tampa, or at 7 community centers across the United States. PD-L1 expression level was determined using the VENTANA PD-L1 (SP263) Assay. EGFR and KRAS mutation status and ALK rearrangements were determined by targeted DNA sequencing; these were obtained from clinical records where targeted DNA sequencing was not performed. TMB was calculated as the total number of somatic mutations per sample. Results: From a total of 136 patients included in the study, 23.5% had tumors with high PD-L1 expression (≥25%). There were no significant differences in patient characteristics, overall survival (OS), and progression-free survival (PFS) between patients with high PD-L1 expression (median OS: 39.5 months; median PFS: 15.8 months) vs low PD-L1 expression (Conclusion: In this retrospective analysis, survival outcomes of patients with advanced NSCLC were comparable by PD-L1 expression level. EGFR and KRAS mutation status were not found to be significantly associated with PD-L1 expression level, while TMB was weakly associated with PD-L1 expression level. Overall, PD-L1 expression level was not observed to be an independent prognostic biomarker in this cohort of patients with advanced NSCLC treated with chemotherapy.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 9512
The ENABLE III randomized controlled trial of concurrent palliative oncology care.
9512 Background: Evidence from randomized controlled trials (RCTs) supports integration of oncology and palliative care; how soon after diagnosis to initiate palliative care has not been defined. Methods: We conducted a ‘fast track’ RCT of patients with advanced cancer in a rural, NCI-designated cancer center, VAMC, and community clinics in NH and VT to determine the effect of immediate vs. delayed (3 months after diagnosis) entry patients into the ENABLE concurrent oncology palliative care intervention on primary outcome measures: QOL (FACIT-pal), symptom impact (Symptom impact subscale of the QUAL-E, mood (CES-D), at 3 and 6 months and survival at 1 year (from enrollment to death or study completion). Other outcomes included: resource use (hospital and ICU days and ER visits-measured by chart review), and quality of EOL care. Results: Participants (immediate n=104; delayed=103) were mean age 65; 52% male; 65% married; 96% white; 42% lung; 46% newly diagnosed with advanced disease; 17% with brain metastases. The estimated treatment effects (TE) using a terminal decline model (Cohen’s d; immediate minus delayed) for patients from randomization to 3 months were: (mean [SE]: .13 (21.39) for QOL (P=.34), -.21 (3.63) for symptom impact (P=.09), and .04 (3.91) for depressed mood (P=.33). 104 participants died (immediate n=49; delayed n=55) during the study. Compared to delayed entry patients, the risk of death (hazard ratio [HR] (95% CI)) was lower for immediate participants at 1 year 0.72 (95% CI, 0.57-0.89) (P=0.003). Median survival for immediate entry patients was 18.3 months (95% CI, 13.2, 28.0) and 11.8 months (95% CI, 9.0, 24.1) for delayed entry patients (P=0.17). Overall median hospital days (3), ICU days (0), and ER visits (1) were identical. 55% (27) of 49 deaths in immediate and 49% (27) of delayed deaths occurred at home. Conclusions: Immediate vs delayed entry patients experienced a significant survival advantage at 1 year; however longitudinal TE were not statistically different. Future research is needed to define mechanisms of survival advantage in palliative care trials. Clinical trial information: NCT01245621.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 9512
The ENABLE III randomized controlled trial of concurrent palliative oncology care.
9512 Background: Evidence from randomized controlled trials (RCTs) supports integration of oncology and palliative care; how soon after diagnosis to initiate palliative care has not been defined. Methods: We conducted a ‘fast track’ RCT of patients with advanced cancer in a rural, NCI-designated cancer center, VAMC, and community clinics in NH and VT to determine the effect of immediate vs. delayed (3 months after diagnosis) entry patients into the ENABLE concurrent oncology palliative care intervention on primary outcome measures: QOL (FACIT-pal), symptom impact (Symptom impact subscale of the QUAL-E, mood (CES-D), at 3 and 6 months and survival at 1 year (from enrollment to death or study completion). Other outcomes included: resource use (hospital and ICU days and ER visits-measured by chart review), and quality of EOL care. Results: Participants (immediate n=104; delayed=103) were mean age 65; 52% male; 65% married; 96% white; 42% lung; 46% newly diagnosed with advanced disease; 17% with brain metastases. The estimated treatment effects (TE) using a terminal decline model (Cohen’s d; immediate minus delayed) for patients from randomization to 3 months were: (mean [SE]: .13 (21.39) for QOL (P=.34), -.21 (3.63) for symptom impact (P=.09), and .04 (3.91) for depressed mood (P=.33). 104 participants died (immediate n=49; delayed n=55) during the study. Compared to delayed entry patients, the risk of death (hazard ratio [HR] (95% CI)) was lower for immediate participants at 1 year 0.72 (95% CI, 0.57-0.89) (P=0.003). Median survival for immediate entry patients was 18.3 months (95% CI, 13.2, 28.0) and 11.8 months (95% CI, 9.0, 24.1) for delayed entry patients (P=0.17). Overall median hospital days (3), ICU days (0), and ER visits (1) were identical. 55% (27) of 49 deaths in immediate and 49% (27) of delayed deaths occurred at home. Conclusions: Immediate vs delayed entry patients experienced a significant survival advantage at 1 year; however longitudinal TE were not statistically different. Future research is needed to define mechanisms of survival advantage in palliative care trials. Clinical trial information: NCT01245621.
- Open Access
- 14 March 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (6) , 1938-1949
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non–small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.
- 14 March 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (6) , 1938-1949
Open AccessRandomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non–small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 8100
Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112
8100 Background: Based on limited data, NSCLC guidelines from ASCO includes non-platinum (non-P) therapy. D0112 provided the highest evidence supporting this guideline. Survival for this non-P and a carboplatin combination were equivalent. Recently, treatment choices and duration are based on subgroups of NSCLC. This report addresses the outcomes for subgroups from this trial. Methods: Eligibility patients (pts) with IIIB/IV NSCLC, performance status (PS) 0–2, and no prior chemotherapy. Randomized pts were stratified by stage (IIIB vs IV) and PS (0–1 vs 2) to arm A: carboplatin + docetaxel or arm B: gemcitabine + docetaxel. Therapy duration following 6 cycles was at the discretion of the investigator. Gender, histology, stage, PS, prior radiation, and central nervous system (CNS) metastasis were identified as independent variables. Multivariable analysis was performed using a proportional hazards regression. Wald test was performed. Treatment effect for each subgroups was evaluated. Results: Median follow-up time for 930 pts was 25.3 mos with 754 deaths. Median survival time (MST) for both treatment groups was 7.9 mos. Non-P arm was non-inferior to the platinum arm, unadjusted hazard ratio of 1.03 (95% confidence interval: 0.89 to 1.18) p = 0.017. By Wald tests, female (p = 0.002), IIIB (p = 0.025), adenocarcinoma (p = 0.002), and PS 0 (p < 0.001) had longer MST. Relative risk for each subgroups was not different for either treatment arm. Pts with non- squamous, no CNS disease and PS 0–1 had a MST of 9.5 mos. 314 pts (34%) received 6 cycles of therapy. Beyond 6 cycles, 163 pts received additional therapy and 151 pts had chemotherapy discontinued without disease progression. MSTs were 15.2 mos (1-yr 66%) and 13.1 mos (1-yr 55%) (p = 0.13), respectively. SAEs were more common for pts with more than 6 cycles (24% of pts) compared to treatment discontinued (16% of pts). Conclusions: For the palliative care of advanced NSCLC, non-P-based chemotherapy provides equivalent survival to carboplatin-based therapy. Females, intrathoracic disease, adenocarcinoma, and good PS do better with either therapy. This trial like others raises questions about the appropriate duration of therapy for incurable NSCLC. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 8100
Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112
8100 Background: Based on limited data, NSCLC guidelines from ASCO includes non-platinum (non-P) therapy. D0112 provided the highest evidence supporting this guideline. Survival for this non-P and a carboplatin combination were equivalent. Recently, treatment choices and duration are based on subgroups of NSCLC. This report addresses the outcomes for subgroups from this trial. Methods: Eligibility patients (pts) with IIIB/IV NSCLC, performance status (PS) 0–2, and no prior chemotherapy. Randomized pts were stratified by stage (IIIB vs IV) and PS (0–1 vs 2) to arm A: carboplatin + docetaxel or arm B: gemcitabine + docetaxel. Therapy duration following 6 cycles was at the discretion of the investigator. Gender, histology, stage, PS, prior radiation, and central nervous system (CNS) metastasis were identified as independent variables. Multivariable analysis was performed using a proportional hazards regression. Wald test was performed. Treatment effect for each subgroups was evaluated. Results: Median follow-up time for 930 pts was 25.3 mos with 754 deaths. Median survival time (MST) for both treatment groups was 7.9 mos. Non-P arm was non-inferior to the platinum arm, unadjusted hazard ratio of 1.03 (95% confidence interval: 0.89 to 1.18) p = 0.017. By Wald tests, female (p = 0.002), IIIB (p = 0.025), adenocarcinoma (p = 0.002), and PS 0 (p < 0.001) had longer MST. Relative risk for each subgroups was not different for either treatment arm. Pts with non- squamous, no CNS disease and PS 0–1 had a MST of 9.5 mos. 314 pts (34%) received 6 cycles of therapy. Beyond 6 cycles, 163 pts received additional therapy and 151 pts had chemotherapy discontinued without disease progression. MSTs were 15.2 mos (1-yr 66%) and 13.1 mos (1-yr 55%) (p = 0.13), respectively. SAEs were more common for pts with more than 6 cycles (24% of pts) compared to treatment discontinued (16% of pts). Conclusions: For the palliative care of advanced NSCLC, non-P-based chemotherapy provides equivalent survival to carboplatin-based therapy. Females, intrathoracic disease, adenocarcinoma, and good PS do better with either therapy. This trial like others raises questions about the appropriate duration of therapy for incurable NSCLC. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 7136
A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC)
7136 Background: Bexarotene (Targretin) is a selective retinoid X receptor (RXR) agonist that appears to prolong survival in pts with NSCLC. To determine mechanisms of action, preclinical studies and a short-term, proof-of-principle clinical trial were performed. Methods: BEAS-2B immortalized human bronchial epithelial cells were treated with bexarotene and effects on EGFR and cell cycle regulatory proteins were determined by Western analyses. To evaluate bexarotene tissue pharmacokinetic (PK) and pharmacodynamic effects, 12 pts with pathologically confirmed stage I and II NSCLC were enrolled. Subjects were given 300 mg/m2/day of bexarotene orally for 7 to 9 days prior to surgical resection. Resected tumor tissue was evaluated for biomarker expression and tumor tissue bexarotene concentrations. Plasma bexarotene concentrations were measured at the time of resection. Biomarker changes were assessed immunohistochemically comparing pre- and post-treatment tissues by pathologists blinded to the tissue origin ...
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 7136
A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC)
7136 Background: Bexarotene (Targretin) is a selective retinoid X receptor (RXR) agonist that appears to prolong survival in pts with NSCLC. To determine mechanisms of action, preclinical studies and a short-term, proof-of-principle clinical trial were performed. Methods: BEAS-2B immortalized human bronchial epithelial cells were treated with bexarotene and effects on EGFR and cell cycle regulatory proteins were determined by Western analyses. To evaluate bexarotene tissue pharmacokinetic (PK) and pharmacodynamic effects, 12 pts with pathologically confirmed stage I and II NSCLC were enrolled. Subjects were given 300 mg/m2/day of bexarotene orally for 7 to 9 days prior to surgical resection. Resected tumor tissue was evaluated for biomarker expression and tumor tissue bexarotene concentrations. Plasma bexarotene concentrations were measured at the time of resection. Biomarker changes were assessed immunohistochemically comparing pre- and post-treatment tissues by pathologists blinded to the tissue origin ...
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7071
Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112)
7071 Background: For patients (pts) with advanced disease and a good performance status (PS) PB therapy is recommended. To date, the survival benefit of a NPB remains unanswered. This trial is designed to compare the overall survival (OS) of NPB vs PB therapy for advanced NSCLC testing for equivalence. Methods: Pt eligibility: pathological stage IIIB/IV NSCLC, PS 0–2, and no prior chemotherapy. Randomized pts were stratified by stage and PS to arm A: carboplatin AUC = 6 + docetaxel 75 mg/m2 every 3 wks (PB) or arm B: gemcitabine 1 gm/m2 + docetaxel 40 mg/m2 days 1 and 8 every 3 wks (NPB). The primary endpoint is OS. Relative risk (RR) and log-rank will be used to establish therapeutic equivalence (RR 0.8–1.2). Planned sample size 928 pts. This trial is monitored by an independent SDMC and source documentation (SD) for all web-based entries is sought. Results: As of December 2003, 732 pts (367 pts arm A vs 365 pts arm B) are enrolled at 87 sites. Pt characteristics are balanced for gender (38% female), age (median 65, range 36–90), PS (14% PS2), stage (76% stage IV) and histology (51% adenocarcinoma, 20% squamous cell). Arm A received 1,538 cycles and 1,335 cycles in arm B. Serious adverse events (SAEs) occurred 135 pts in arm A and 184 in arm B. Only 30% of all SAEs are attributed to therapy. There were 2 treatment-related deaths, one on each arm. In July 2003 at a predefined interim analysis with 97% of the data SD, 250 deaths occurred among 620 randomized pts. The OS yielded p = 0.38. The 1-year survival rate was 45% for PB and 42% for NPB. The pre-specified stopping rule for superiority was p = 0.01. The SDMC recommended continuation. We anticipate completion by May 2004 and presentation of the final data sets in June 2004. Conclusions: At the predefined interim analysis, there appears to be no statistical survival advantage for platinum or non-platinum-based therapy. At present, there appear to be qualitative and quantitative differences in SAEs. Upon completion, we will definitively comment on the equivalence of a non-platinum-based treatment for this disease.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 7071
Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112)
7071 Background: For patients (pts) with advanced disease and a good performance status (PS) PB therapy is recommended. To date, the survival benefit of a NPB remains unanswered. This trial is designed to compare the overall survival (OS) of NPB vs PB therapy for advanced NSCLC testing for equivalence. Methods: Pt eligibility: pathological stage IIIB/IV NSCLC, PS 0–2, and no prior chemotherapy. Randomized pts were stratified by stage and PS to arm A: carboplatin AUC = 6 + docetaxel 75 mg/m2 every 3 wks (PB) or arm B: gemcitabine 1 gm/m2 + docetaxel 40 mg/m2 days 1 and 8 every 3 wks (NPB). The primary endpoint is OS. Relative risk (RR) and log-rank will be used to establish therapeutic equivalence (RR 0.8–1.2). Planned sample size 928 pts. This trial is monitored by an independent SDMC and source documentation (SD) for all web-based entries is sought. Results: As of December 2003, 732 pts (367 pts arm A vs 365 pts arm B) are enrolled at 87 sites. Pt characteristics are balanced for gender (38% female), age (median 65, range 36–90), PS (14% PS2), stage (76% stage IV) and histology (51% adenocarcinoma, 20% squamous cell). Arm A received 1,538 cycles and 1,335 cycles in arm B. Serious adverse events (SAEs) occurred 135 pts in arm A and 184 in arm B. Only 30% of all SAEs are attributed to therapy. There were 2 treatment-related deaths, one on each arm. In July 2003 at a predefined interim analysis with 97% of the data SD, 250 deaths occurred among 620 randomized pts. The OS yielded p = 0.38. The 1-year survival rate was 45% for PB and 42% for NPB. The pre-specified stopping rule for superiority was p = 0.01. The SDMC recommended continuation. We anticipate completion by May 2004 and presentation of the final data sets in June 2004. Conclusions: At the predefined interim analysis, there appears to be no statistical survival advantage for platinum or non-platinum-based therapy. At present, there appear to be qualitative and quantitative differences in SAEs. Upon completion, we will definitively comment on the equivalence of a non-platinum-based treatment for this disease.